- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Beam Therapeutics CEO Sells Over $700K in Stock
Insider transaction raises questions about company's future direction
Apr. 7, 2026 at 8:21am
Got story updates? Submit your updates here. ›
An insider stock sale by Beam Therapeutics' CEO raises questions about the future of the gene-editing biotech firm.Philadelphia TodayBeam Therapeutics Inc. CEO John Evans sold 30,078 shares of the company's stock in a transaction on April 1st, 2026, generating over $700,000 in proceeds. The sale was made to cover tax withholding obligations related to the vesting of equity awards, according to a legal filing with the SEC.
Why it matters
Insider stock sales can often signal a lack of confidence in a company's future prospects, raising concerns for investors. Beam Therapeutics is a closely watched biotech firm focused on pioneering gene-editing technologies, so this transaction by the CEO is likely to be closely scrutinized by the market.
The details
The shares were sold at an average price of $24.58, for a total transaction value of $739,317.24. Following the sale, the CEO directly owned 1,047,205 shares of the company's stock, valued at $25,740,298.90. This represented a 2.79% decrease in his ownership stake.
- The stock sale took place on Wednesday, April 1st, 2026.
The players
John Evans
CEO of Beam Therapeutics Inc., a biotechnology company focused on developing precision genetic medicines.
Beam Therapeutics Inc.
A NASDAQ-listed biotechnology company headquartered in Cambridge, Massachusetts, specializing in base editing technology for genetic therapies.
What’s next
Investors will likely be closely monitoring Beam Therapeutics' stock performance and any further insider transactions in the coming weeks to gauge the company's outlook.
The takeaway
This CEO stock sale raises questions about the future direction of Beam Therapeutics, a prominent player in the rapidly evolving gene-editing space. Insider transactions can provide valuable signals to the market, and this sale will be scrutinized for what it may indicate about the company's prospects.
